<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222114</url>
  </required_header>
  <id_info>
    <org_study_id>LP0190415</org_study_id>
    <nct_id>NCT04222114</nct_id>
  </id_info>
  <brief_title>Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis</brief_title>
  <official_title>A Two-stage,Multi-center,Open-label, Randomized,Controlled Trial Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LintonPharm Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LintonPharm Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 297 subjects are estimated to enroll in the study, with 15 eligible subjects&#xD;
      enrolled in the 1st stage at most and 282 evaluable subjects in the 2nd stage. All subjects&#xD;
      are adult patients with age over 18-year-old; they must be diagnosed with recurrent or&#xD;
      metastatic gastric cancer with peritoneal metastasis at the time of enrollment; and failed at&#xD;
      least prior two standard systemic anti-cancer therapies for recurrent or metastatic gastric&#xD;
      cancer, before enrollment.&#xD;
&#xD;
      In the first stage, pharmacokinetic characteristics and preliminary safety of catumaxomab&#xD;
      will be explored in Asian patients with gastric cancer ; in Cohort A, the enrolled subjects&#xD;
      will receive the first infusion at 10μg on day 1, which will be increased to 20 μg, 50 μg and&#xD;
      150 μg on days 4, 8 and 11, respectively. 42 days are defined as a cycle. From the second&#xD;
      cycle, catumaxomab will be changed to 20 μg, 50 μg, 150 μg on days 1, 4, 8 respectively. In&#xD;
      Cohort B, 28 days are defined as a cycle. It is estimated to enroll 6 subjects in each cohort&#xD;
      first.&#xD;
&#xD;
      In the second stage, approximate 282 subjects who meet the enrollment criteria are randomized&#xD;
      into either catumaxomab infusion group (catumaxomab group) or treatment of investigator&#xD;
      choice group (IC group), at a ratio of 2:1.&#xD;
&#xD;
      Subjects at the first and second stages will continue the treatment until one of the&#xD;
      following conditions occurs:1)Significant progression of tumor lesions, including but not&#xD;
      limited to peritoneal metastases lesions and/or ascites; 2)Intolerable toxicity; 3)The&#xD;
      investigator believes that patients need to withdraw from the study and receive other&#xD;
      treatment;4)death;5)Withdrawal of informed consent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the time from randomization to death for anyreason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>According to RECIST V1.1 criteria, defined as the timefrom randomization to progression disease (PD) or death for any reason,which ever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free interval of peritoneal metastatic lesions</measure>
    <time_frame>1 year</time_frame>
    <description>to subjects with ≥300 ml of ascites, defined as the time from first intra-peritoneal infusion to ascites progression based on the five--point method2; to subjects without ascites or &lt;300 ml, it is defined as the time from the first intra-peritoneal infusion to thetimeof progression oftheintra-peritoneal lesion according to theRECISTV1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>According to RECIST V1.1 criteria, defined as the proportion of subjects with response achieving CR or PR;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate(CBR)</measure>
    <time_frame>1 year</time_frame>
    <description>According to RECIST V1.1 criteria,defined as the proportion of subjects with response achieving SD,PR or CR;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>1 year</time_frame>
    <description>According to RECIST V1.1 criteria, defined as the time from the response to the confirmation of PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascites Remission Duration</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the time from the 1st as cites remission to as cites progression,according to the five-point method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of treatment-emergent adverse events (TEAEs) in the catumaxomab and IC groups</measure>
    <time_frame>1 year</time_frame>
    <description>Compared according to the National Cancer Institute Common Terminology Standard for Adverse Events (NCI-CTCAE)v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of DLT</measure>
    <time_frame>1 year</time_frame>
    <description>it will be evaluated in the first stage only. It is defined as the incidence of DLT from the first infusion to 6 weeks after wards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of anti-drug antibodies(ADA) to catumaxomab in serum</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of anti-drug antibodies(ADA) to catumaxomab in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tendency of theperipheral blood lymphocyte counts change associated with the intra-peritoneal infusion of catumaxomab</measure>
    <time_frame>1 year</time_frame>
    <description>Tendency of theperipheral blood lymphocyte counts change associated with the intra-peritoneal infusion of catumaxomab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Catumaxomab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IC group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IC group is defined as the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catumaxomab</intervention_name>
    <description>The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.</description>
    <arm_group_label>Catumaxomab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The treatment of investigator choice</intervention_name>
    <description>the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.</description>
    <arm_group_label>IC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent forms have been provided.&#xD;
&#xD;
          2. Willing to be complaint with the study procedures during the study.&#xD;
&#xD;
          3. Male or female, age≥18years old when signing informed consents.&#xD;
&#xD;
          4. Histologically or cytologically confirmed as gastricadeno carcinoma.&#xD;
&#xD;
          5. Evaluable and/or non-evaluable lesions according to RECISTV1.1 criteria.&#xD;
&#xD;
          6. Diagnosed as gastric cancer with peritoneal metastases (Imaging finding, previous&#xD;
             surgicalpathology, ascites/peritoneal effusion cytology positive).&#xD;
&#xD;
          7. Treatment failure after receiving at least prior two standard systemic anti-cancer&#xD;
             therapies for recurrent or metastatic gastric cancer.&#xD;
&#xD;
          8. Recovered from any toxicity due to previous treatment (Grade 0-1 according to&#xD;
             NCI-CTCAEv5.0).&#xD;
&#xD;
          9. Estimated survival length≥3months.&#xD;
&#xD;
         10. Eastern Oncology Cooperative Group(ECOG) performance status 0-2.&#xD;
&#xD;
         11. The laboratory test values during the screening period are in accordance with the&#xD;
             following table：ANC(absolute neutrophil count)≥ 1.5 × 10^9/L， Hemoglobin≥ 80&#xD;
             g/L，Platelet≥ 100 × 10^9/L， Lymphocyte percentage≥13%，Serum Bilirubin≤ 1.25 x ULN(or&#xD;
             2.5 x ULN if there is Gilbert)， AST and ALT ≤ 2.5 × ULN without liver metastasis（or≤ 5&#xD;
             × ULN if liver metastasis ），Serum creatinine ≤ 2.0 mg/dL (or Calculated creatinine&#xD;
             clearance≥30 mL/min).&#xD;
&#xD;
         12. For women of childbearing potential: use an efficient method for contraception at&#xD;
             least 1 month prior to screening and agree to use this method for contraception during&#xD;
             the study period and extended period specified after the study intervention.&#xD;
&#xD;
         13. For men with fertility potential: use condoms or other methods to ensure effective&#xD;
             contraception for sexual partners.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected of being allergic to catumaxomab or similar antibodies.&#xD;
&#xD;
          2. Previously received anti-tumor treatments, including other anti-tumor investigational&#xD;
             drugs, chemotherapy, immunotherapy, biological agents, hormone therapy, radiation&#xD;
             therapy (except local radiation therapy for pain relief), etc., the interval between&#xD;
             the last treatment and the first peritoneal infusion is ≤ 21days.&#xD;
&#xD;
          3. There is extensive liver metastasis(the tumor volume is estimated to be≥50% of the&#xD;
             total liver volume by imaging).&#xD;
&#xD;
          4. Known tumor in tra-cranial metastases.&#xD;
&#xD;
          5. The following diseases have not been resolved to CTCAE grade 0-1 3 days before the&#xD;
             first infusion:&#xD;
&#xD;
               -  Uncontrolled acute and chronic infections such as pneumonia, biliary infection,&#xD;
                  hepatitis B virus infection and hepatitis C virus infection,etc.;&#xD;
&#xD;
               -  Acute or chronic pancreatitis;&#xD;
&#xD;
               -  Diarrhea;&#xD;
&#xD;
               -  Dyspnea&#xD;
&#xD;
          6. NYHA Class 3 or 4.&#xD;
&#xD;
          7. Symptoms and signs of related cardiovascular diseases: including myocardial&#xD;
             infarction, congestive heart failure,arrhythmia.&#xD;
&#xD;
          8. Known cerebrovascular accidents.&#xD;
&#xD;
          9. Intestinal obstruction occurred 30 days before the first dose.&#xD;
&#xD;
         10. Imaging diagnosis of portal vein obstruction, including tumor compression or portal&#xD;
             thrombosis,cancer thrombus.&#xD;
&#xD;
         11. History of autoimmune diseases (e.g.,inflammatory bowel disease, idiopathic&#xD;
             thrombocytopenic purpura, systemic lupus erythematosus, autologous hemolytic anemia,&#xD;
             rheumatoid arthritis,etc.).&#xD;
&#xD;
         12. Patients with known HIV serology positive, hepatitis C infection and/or hepatitis B&#xD;
             (Except the patients with HepBsAg or core antibody positive and responding to&#xD;
             antiviral therapy against hepatitis B who are allowed to participate in the study;&#xD;
             Notes: HepBsAg-negative patients at screening, or patients are undergoing treatment&#xD;
             with interferon-2a [IFN] or peginterferon-2a [Peg-IFN] and hepatitis B virus [HBV] DNA&#xD;
             &lt; 2000 international units [IU], or subjects who are receiving nucleoside [acid]&#xD;
             analogues at screening and HBV DNA below the lower limit of normal [LLN] are eligible&#xD;
             to participate in the study).&#xD;
&#xD;
         13. Pregnancy or breast feeding during study treatment and follow-up.&#xD;
&#xD;
         14. Patients with confirmed history of neurological or psychotic disorders, including&#xD;
             epilepsy or dementia.&#xD;
&#xD;
         15. Other serious systemic conditions that may limit the patient's participation in this&#xD;
             study (eg uncontrolled diabetes, cardiovascular and cerebrovascular disease, severe&#xD;
             gastrointestinal disease,etc.).&#xD;
&#xD;
         16. Any other condition that, in the discretion of the investigator will make patients&#xD;
             exposed to unnecessary risks and unsuitable for participation in this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Zhang</last_name>
      <phone>010-88196861</phone>
      <email>zlei090903@163.com</email>
    </contact>
    <investigator>
      <last_name>Lin Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ma</last_name>
      <phone>010-66119025</phone>
      <email>bdyyec@163.com</email>
    </contact>
    <investigator>
      <last_name>Shikai Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ying lin</last_name>
      <phone>020-87330631</phone>
      <email>zsyyicc2020@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Shirong Cai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiling Li</last_name>
      <phone>(0371) 6558 8251</phone>
      <email>13937176523@163.com</email>
    </contact>
    <investigator>
      <last_name>Jufeng Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University.</name>
      <address>
        <city>Jilin</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyuan Zhao</last_name>
      <phone>0431-88782013</phone>
      <email>kjkzhaoliyuan@126.com</email>
    </contact>
    <investigator>
      <last_name>wei Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NA NA</last_name>
      <phone>+82-02-2019-4601-3</phone>
      <email>gsirb@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Yong Won Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NA NA</last_name>
      <phone>+82-31-219-5569/4061/4062</phone>
      <email>ougi96@aumc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hei-Cheul Jeung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In Cho Hyun</last_name>
      <phone>+82-2-3410-1710</phone>
      <email>hyunin.cho@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Kim Seung Tae</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Mina</last_name>
      <phone>+82-2-2258-8194</phone>
      <email>seoul_irb@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>In-Ho Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>800</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NA NA</last_name>
      <phone>886-7-3121101</phone>
      <email>irb-app@kmuh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Jaw-Yuan Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NA NA</last_name>
      <phone>+886-04-22052121#1941</phone>
      <email>rrec@mail.cmu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Li-Yuan Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital, Liouying</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NA NA</last_name>
      <phone>+886-06-281281#53720</phone>
      <email>csr2930@mail.chimei.org.tw</email>
    </contact>
    <investigator>
      <last_name>Cheng-Yao Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeh Jung</last_name>
      <phone>+886-6-2353535 ext 4826</phone>
      <email>n993406@mail.hosp.ncku.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Chia-Jui Yen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Peritoneal metastasis</keyword>
  <keyword>catumaxomab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Catumaxomab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

